Product/Composition:- | Secukinumab |
---|---|
Strength:- | 150 mg/mL |
Form:- | Injection |
Reference Brands:- | Cosentyx |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Cosentyx (Secukinumab) 150 mg/mL is approved for psoriasis and arthritis. Available as autoinjector and syringe. Ideal for global pharma B2B supply.
Secukinumab (Cosentyx®) is a leading IL-17A monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It is available as a 150 mg/mL prefilled syringe or autoinjector, designed for convenient subcutaneous administration. Trusted globally under the Cosentyx brand by Novartis, it is used in dermatology and rheumatology settings across the US and EU. Manufactured under GMP/ICH-compliant standards, Secukinumab is ideal for B2B pharmaceutical buyers, including hospitals, clinics, and specialty pharmacies. Contact us for bulk export, regulatory support, and competitive pricing.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications